Open Access

Long‑lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib

  • Authors:
    • Tatsuro Jo
    • Kazuhiro Noguchi
    • Shizuka Hayashi
    • Sadaharu Irie
    • Risa Hayase
    • Haruna Shioya
    • Youhei Kaneko
    • Kensuke Horio
    • Jun Taguchi
  • View Affiliations

  • Published online on: December 29, 2017     https://doi.org/10.3892/ol.2017.7720
  • Pages: 2935-2938
  • Copyright: © Jo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)‑chronic myeloid leukemia (CML), as CMLs harbor the BCR‑ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have been observed in patients treated with dasatinib, but not other TKIs. The LGLs have been reported to be primarily natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In the present study, a CP‑CML patient who has maintained molecular response 5 for >2.4 years after stopping dasatinib was reported. Memory and effector CTLs and NK cells, were observed after 2.4 years of treatment‑free remission, despite the fact that lymphocyte counts are not elevated in the patient. These results suggest that dasatinib may induce cellular immunity, including NK cells and CTLs and this cellular immunity may be maintained for a long period following cessation of dasatinib. The results suggest that this cellular immunity may provide a long‑term cure without the need for continued TKI treatment.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jo T, Noguchi K, Hayashi S, Irie S, Hayase R, Shioya H, Kaneko Y, Horio K and Taguchi J: Long‑lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib. Oncol Lett 15: 2935-2938, 2018
APA
Jo, T., Noguchi, K., Hayashi, S., Irie, S., Hayase, R., Shioya, H. ... Taguchi, J. (2018). Long‑lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib. Oncology Letters, 15, 2935-2938. https://doi.org/10.3892/ol.2017.7720
MLA
Jo, T., Noguchi, K., Hayashi, S., Irie, S., Hayase, R., Shioya, H., Kaneko, Y., Horio, K., Taguchi, J."Long‑lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib". Oncology Letters 15.3 (2018): 2935-2938.
Chicago
Jo, T., Noguchi, K., Hayashi, S., Irie, S., Hayase, R., Shioya, H., Kaneko, Y., Horio, K., Taguchi, J."Long‑lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib". Oncology Letters 15, no. 3 (2018): 2935-2938. https://doi.org/10.3892/ol.2017.7720